Strikingly, troglitazone aswell as Δ2-troglitazone is approximately 10 fold more potent inhibitors of TGF-β1 release thanof glioma cell proliferation, suggesting that both effects may not be essentiallyinterlinked. The gene discussed is TGFB1; the disease is glioma.